Kexing Biopharm Partners with BioMap on AI-Driven Macromolecular Drug Development
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with US biotech firm BioMap...
SHA: 688136
Kexing Biopharm and Hinova Forge Alliance to Expand Global Market Reach
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced this week a strategic alliance with compatriot...
Tonghua Dongbao’s Tongboli Under GMP Inspection in Egypt
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced that the on-site Good Manufacturing Practice (GMP) inspection...
Kexing Biopharm and Bio-Sincerity Pharmaceutical Form Strategic Alliance
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) and Hangzhou Bio-Sincerity Pharmaceutical Technology Co., Ltd. (SHE:...
Kexing Biopharm’s GB05 Receives FDA Approval for Pediatric RSV Infections
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced that it has received clinical trial approval...
Kexing Biopharm and Bio-Thera Solutions Form Alliance for Global Expansion
China-based Kexing Biopharm (SHA: 688136) and Bio-Thera Solutions Ltd (SHA: 688177) have formed a strategic...
Kexing and Kelun Partner to Expand Overseas Business for Generic Drugs and Therapies
China-based firms Kexing Pharmaceutical (SHA: 688136) and Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) have...
Kexing Pharmaceutical Partners with Shandong Boan for Biosimilar Commercialization in Hong Kong and Macau
China-based Kexing Pharmaceutical (SHA: 688136) has entered into a commercialization cooperation agreement with fellow Chinese...
MabPharm’s CMAB807 Biosimilar Infliximab Approved in Pakistan
Taizhou-based monoclonal antibody (mAb) biosimilar specialist MabPharm Ltd (HKG: 2181) has announced the receipt of...
MabPharm’s CMAB807 Biosimilar Receives Market Approval in Indonesia and Peru
Taizhou-based MabPharm Ltd (HKG: 2181), a specialist in monoclonal antibody (mAb) biosimilars, has announced the...
Zhejiang Haichang Biotech Secures EU Approval for Apexelsin: A New Hope in Cancer Treatment
Zhejiang Haichang Biotech Co., Ltd, a partner of China-based Kexing Pharmaceutical (SHA: 688136), has secured...
Kexing Pharmaceutical Secures NMPA Approval for Childhood Growth Hormone Deficiency Study
Kexing Pharmaceutical (SHA: 688136), based in China, has received approval from the National Medical Products...
Kexing Pharmaceutical Secures Global Rights for Qingfeng’s Generic Olaparib
China’s Kexing Pharmaceutical (SHA: 688136) has secured a global commercialization licensing agreement with Qingfeng Pharmaceutical...
Kexing Pharmaceutical Secures Rights for Chia Tai Tianqing’s Generic Ibrance in 11 Countries
Kexing Pharmaceutical (SHA: 688136), based in China, has entered into an international collaboration agreement with...
Kexing Pharmaceutical Partners with Yabao to Distribute Generic Nexavar in Ten Countries
China-based Kexing Pharmaceutical (SHA: 688136) has entered into an overseas cooperation agreement with fellow domestic...
Kexing Pharmaceutical Enters Global Licensing Agreement with Xiling Lab for Eribulin Generic
China-based Kexing Pharmaceutical (SHA: 688136) has entered into a global licensing and supply agreement with...
Convalife Pharmaceuticals Gets NMPA Approval for Generic Neratinib Clinical Study
Shanghai-based Convalife Pharmaceuticals has announced that it has received approval from the National Medical Products...
Kexing Pharmaceutical Secures Commercial Rights for Convalife’s Neratinib Generic Outside China
China-based Kexing Pharmaceutical (SHA: 688136) has announced a licensing agreement with compatriot firm Convalife, securing...
Kexing Pharmaceutical Initiates Phase I Trial for IFN-Alpha-1b Inhalation Solution
China-based Kexing Pharmaceutical (SHA: 688136) has announced the enrollment of the first subject and dosing...
Tonghua Dongbao Licenses Biosimilar Victoza to Kexing for Emerging Markets
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced a licensing agreement with compatriot firm Kexing Pharmaceutical...